Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003292
Status:
TERMINATED
Last Update Posted:
2013-11-08
First Post:
1999-11-01
Brief Title:
S9624 Ifosfamide in Treating Patients With Meningeal Tumors
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Study Overview
Official Title:
S9624 Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors
Status:
TERMINATED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
lack of accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically
PURPOSE Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically
Detailed Description:
OBJECTIVES
Estimate failure free survival overall survival and response in patients with residual or recurrentprogressive aggressive meningeal tumors malignant meningioma hemangiopericytoma and primary nervous system sarcoma treated with ifosfamide
Evaluate toxicities of ifosfamide in this patient population
OUTLINE All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course Patients are evaluated for responseprogression after every 2 courses Patients with stable disease receive up to 8 courses of therapy Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year then every 6 months thereafter
PROJECTED ACCRUAL Approximately 35 patients will be accrued for this study
Estimate failure free survival overall survival and response in patients with residual or recurrentprogressive aggressive meningeal tumors malignant meningioma hemangiopericytoma and primary nervous system sarcoma treated with ifosfamide
Evaluate toxicities of ifosfamide in this patient population
OUTLINE All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course Patients are evaluated for responseprogression after every 2 courses Patients with stable disease receive up to 8 courses of therapy Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year then every 6 months thereafter
PROJECTED ACCRUAL Approximately 35 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA032102 | NIH | SWOG | httpsreporternihgovquickSearchU10CA032102 |
| S9624 | OTHER | None | None |